Cargando…
Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly direct...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036683/ https://www.ncbi.nlm.nih.gov/pubmed/33801752 http://dx.doi.org/10.3390/ijms22073480 |
_version_ | 1783676967712718848 |
---|---|
author | Field, Des Considine, Kiera O’Connor, Paula M. Ross, R. Paul Hill, Colin Cotter, Paul D. |
author_facet | Field, Des Considine, Kiera O’Connor, Paula M. Ross, R. Paul Hill, Colin Cotter, Paul D. |
author_sort | Field, Des |
collection | PubMed |
description | Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly directed to veterinary applications, do not require a lengthy milk withholding period and that will not have a negative impact on the growth of lactic acid bacteria involved in downstream dairy fermentations. Nisin is the prototypical lantibiotic, a family of highly modified antimicrobial peptides that exhibit potent antimicrobial activity against many Gram-positive microbes, including human and animal pathogens including species of Staphylococcus and Streptococcus. Although not yet utilized in the area of human medicine, nisin is currently applied as the active agent in products designed to prevent bovine mastitis. Over the last decade, we have harnessed bioengineering strategies to boost the specific activity and target spectrum of nisin against several problematic microorganisms. Here, we screen a large bank of engineered nisin derivatives to identify novel derivatives that exhibit improved specific activity against a selection of staphylococci, including mastitis-associated strains, but have unchanged or reduced activity against dairy lactococci. Three such peptides were identified; nisin A M17Q, nisin A T2L and nisin A HTK. |
format | Online Article Text |
id | pubmed-8036683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80366832021-04-12 Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis Field, Des Considine, Kiera O’Connor, Paula M. Ross, R. Paul Hill, Colin Cotter, Paul D. Int J Mol Sci Article Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly directed to veterinary applications, do not require a lengthy milk withholding period and that will not have a negative impact on the growth of lactic acid bacteria involved in downstream dairy fermentations. Nisin is the prototypical lantibiotic, a family of highly modified antimicrobial peptides that exhibit potent antimicrobial activity against many Gram-positive microbes, including human and animal pathogens including species of Staphylococcus and Streptococcus. Although not yet utilized in the area of human medicine, nisin is currently applied as the active agent in products designed to prevent bovine mastitis. Over the last decade, we have harnessed bioengineering strategies to boost the specific activity and target spectrum of nisin against several problematic microorganisms. Here, we screen a large bank of engineered nisin derivatives to identify novel derivatives that exhibit improved specific activity against a selection of staphylococci, including mastitis-associated strains, but have unchanged or reduced activity against dairy lactococci. Three such peptides were identified; nisin A M17Q, nisin A T2L and nisin A HTK. MDPI 2021-03-27 /pmc/articles/PMC8036683/ /pubmed/33801752 http://dx.doi.org/10.3390/ijms22073480 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Field, Des Considine, Kiera O’Connor, Paula M. Ross, R. Paul Hill, Colin Cotter, Paul D. Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title | Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title_full | Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title_fullStr | Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title_full_unstemmed | Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title_short | Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis |
title_sort | bio-engineered nisin with increased anti-staphylococcus and selectively reduced anti-lactococcus activity for treatment of bovine mastitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036683/ https://www.ncbi.nlm.nih.gov/pubmed/33801752 http://dx.doi.org/10.3390/ijms22073480 |
work_keys_str_mv | AT fielddes bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis AT considinekiera bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis AT oconnorpaulam bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis AT rossrpaul bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis AT hillcolin bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis AT cotterpauld bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis |